Takeda Ventures

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

PSI provides life-saving information, products, and services to tackle some of the world’s most pressing health problems so that people can lead healthier, happier, and more productive lives.

Nabla Bio is a biotechnology company that uses artificial intelligence and lab technologies to rationally design novel proteins for drug development. They aim to create medicines and improve nutrition by engineering proteins with enhanced qualities.

Maia Oncology operates a virtual cancer care coordination platform, serving as a comprehensive primary care clinic for cancer patients and survivors. The platform tracks patient outcomes, including hospitalizations, ER visits, and new comorbidities, enabling patients to navigate cancer-related toxicities and long-term complications.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Project Scientist is an organization focused on advancing girls and women in STEM across ages from 4 to PhD level. It provides essential support tailored to each stage of a future scientist's life for girls and women, enabling progression through education and careers in science, technology, engineering, and mathematics. Based on extensive research on current trends and practices, it has developed a robust three-phase program pipeline designed to serve as a national model for expanding STEM interests and participation across all ages.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Zelluna Immunotherapy is a Norwegian biopharmaceutical company focused on developing T-cell receptor based cancer immunotherapies. Founded in 2016 and based in Oslo, it pursues a pipeline of tumor-specific TCRs, many derived from patients who showed long-term survival after peptide-based cancer vaccine trials at the Norwegian Radium Hospital/Oslo University Hospital. The company aims to enable immune cells to recognize a broad range of cancers with safety and durability. It operates in collaboration with Oslo Cancer Cluster and is located at the Oslo Cancer Cluster Innovation Park near major hospital facilities and GMP-certified cellular therapy capabilities.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Integra Therapeutics is a biotechnology company focused on advancing gene editing technologies to address various diseases. It develops innovative gene writing tools that enhance the capabilities of gene therapy, aiming to meet the specific needs of patients. By integrating the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in gene editing. The company's approach enables scientists to introduce DNA into genomes using sequence-specific DNA binding proteins, facilitating the development of more effective gene therapies.

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

BridGene Biosciences is a biotechnology company that employs chemoproteomic technology to discover and develop small molecules. It uses covalent small molecules for proteome-wide screening in live cells, enabling the targeting of traditionally undruggable proteins.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Emendo Biotherapeutics is a biotechnology company focused on advancing genome editing technologies to develop genetic medicines. Established by a team of experts with backgrounds in protein engineering and DNA repair from prestigious institutions, Emendo aims to tackle the challenges associated with gene therapy. By innovating and transforming existing tools, the company seeks to address diseases and disorders that are presently deemed untreatable. Emendo's approach fuses diverse scientific disciplines with creative problem-solving, enabling the development of advanced gene editing solutions that enhance the efficacy of gene therapy and expand its potential applications. Through this commitment to pushing the boundaries of science, Emendo Biotherapeutics strives to fulfill the promise of gene editing for improved patient outcomes.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR, targeting neurodegenerative and neuroinflammatory diseases. The company utilizes unique computational methods to develop a series of novel and selective molecules, which are validated through clinically relevant assays. This approach aims to address issues such as memory consolidation impairment and enhance long-term memory in patients. In 2019, ProteKt Therapeutics graduated from the FutuRx accelerator and subsequently raised $4 million in a pre-A funding round to support its innovative research and development efforts.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Axcelead specializes in early-stage drug discovery services. It offers integrated solutions, combining scientific expertise, robust intellectual property protection, and state-of-the-art facilities to support clients from exploratory research to optimizing candidate compounds.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

Bsense Bio Therapeutics develops small-molecule therapeutics for sensory hyperexcitability-related disorders. It pursues a novel approach that targets multiple hyperexcitability mechanisms with a single compound, focusing on two cation channels: a ligand-gated cation channel and a voltage-gated potassium channel, to improve efficacy and safety.

Reborna Biosciences specializes in researching and developing treatments for genetic diseases, focusing on areas with unmet medical needs. The company's core technology enables low-molecular compounds to target ribonucleic acid (RNA), leading to the creation of new disease-modifying drugs for patients suffering from rare genetic diseases such as spinal muscular atrophy.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Shire is a global biopharmaceutical company focused on developing and marketing therapies for rare diseases. It maintains a broad portfolio across hematology, immunology, neuroscience, ophthalmology, internal medicine and endocrine disorders, and hereditary angioedema. The company operates a worldwide sales and marketing network with direct marketing in the United States, Canada, the United Kingdom, Ireland, France, Germany, Italy and Spain. It emphasizes patient-focused care and aims to deliver innovative therapies to patients with rare diseases worldwide.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, designing, optimizing, and producing stereopure oligonucleotides through its PRISM platform. The company aims to address genetically defined diseases by reducing harmful protein expression or correcting dysfunctional proteins, employing modalities such as RNA editing, antisense silencing, and RNA interference. Its programs span neurological and neuromuscular conditions, reflecting an emphasis on central nervous system targets. Wave collaborates with Pfizer and Takeda on research, development, and commercialization of stereopure oligonucleotide therapeutics and antisense therapies. Founded in 2012 and based in Singapore, the company seeks to unlock the broader potential of RNA medicines to improve patient outcomes.

SEEDSUPPLY is a research and development company based in Fujisawa, Kanagawa, Japan, that specializes in creating medical and agricultural chemical products. Established in May 2017 as a spin-off from Takeda Pharmaceutical Company Limited, SEEDSUPPLY operates a drug discovery platform focused on the development of small molecule drugs. The company utilizes binder selection technology to address drug targets that are typically difficult to analyze with conventional high-throughput screening methods. This innovative approach enables medical professionals to explore new possibilities in the discovery of drug candidate compounds, contributing to advancements in medical treatments.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Scohia Pharma is a Fujisawa, Japan-based biopharmaceutical company focused on researching, designing, and developing therapies for metabolic, cardiovascular, and renal diseases. Its work targets lifestyle-related conditions such as obesity, diabetes, dyslipidemia, and hypertension, with an emphasis on delivering treatments that improve patient outcomes through research and development across metabolic and renal disorders.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Emendo Biotherapeutics is a biotechnology company focused on advancing genome editing technologies to develop genetic medicines. Established by a team of experts with backgrounds in protein engineering and DNA repair from prestigious institutions, Emendo aims to tackle the challenges associated with gene therapy. By innovating and transforming existing tools, the company seeks to address diseases and disorders that are presently deemed untreatable. Emendo's approach fuses diverse scientific disciplines with creative problem-solving, enabling the development of advanced gene editing solutions that enhance the efficacy of gene therapy and expand its potential applications. Through this commitment to pushing the boundaries of science, Emendo Biotherapeutics strives to fulfill the promise of gene editing for improved patient outcomes.

Bioniz Therapeutics, Inc. is a biopharmaceutical company based in Irvine, California, established in 2009. It specializes in discovering and developing innovative peptide therapeutics aimed at treating immune diseases and cancer. The company's pipeline includes BNZ-1, a selective inhibitor targeting interleukin cytokines IL2, IL9, and IL15, which are significant contributors to conditions such as HTLV-1 Associated Myelopathy and T-cell leukemias. Additionally, Bioniz is developing IL-15 and IL-21 inhibitors, as well as BNZ-3, an early-stage asset focused on inhibiting IL-4, IL-9, and IL-21 cytokines. Bioniz Therapeutics is committed to advancing its lead technologies through proof of concept and preclinical studies, with the goal of partnering for clinical trials and eventual commercialization.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Aquinnah Pharmaceuticals, Inc., founded in 2014 and based in Cambridge, Massachusetts, is a pharmaceutical company dedicated to developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on innovative research aimed at modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its specialized approach, Aquinnah Pharmaceuticals aims to address critical unmet medical needs in the field of neurodegeneration.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. The company specializes in developing novel small-molecule antiviral therapeutics through its innovative drug discovery platform, which utilizes cell-free protein synthesizing systems. This platform enables the identification of small molecule drugs that may be overlooked by traditional pharmaceutical screening methods. Prosetta Biosciences is engaged in collaborative efforts with both commercial and non-profit partners to advance compounds targeting a variety of human diseases, including oncology, neurodegenerative disorders, and infectious diseases. The company's focus on modulating the assembly of multi-protein complexes within cells positions it as a significant player in the biopharmaceutical sector.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Encycle Therapeutics, Inc. is a biotechnology company based in Toronto, Canada, that focuses on developing innovative drug candidates using its proprietary platform technology for the rapid synthesis of drug-like macrocycles and membrane-permeable nacellins. These nacellins are designed to target challenging intracellular protein-protein interactions, offering a potential alternative to traditional small molecules and biologics, such as monoclonal antibodies. The company has established collaborations with various pharmaceutical firms to build a screening library of nacellins, many of which demonstrate cell-permeable and drug-like characteristics. Encycle is actively pursuing the independent development of nacellins aimed at specific targets, including integrin alpha-4-beta-7 for inflammatory bowel disease and SMURF2 for fibrosis. Its lead program seeks to create orally bioavailable inhibitors of integrin alpha-4-beta-7 that promise improved safety and reduced immunogenicity compared to existing biologics targeting this protein.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

BioMotiv is a therapeutic accelerator that develops a portfolio of novel medicines. As the mission-aligned development arm of The Harrington Project for Discovery and Development, it works with University Hospitals to advance breakthrough drugs from discovery to market. The Harrington Project is a large initiative backed by a $250 million commitment to accelerate therapeutic innovation. By coordinating upstream discovery with downstream development, BioMotiv seeks to shorten the pathway to new treatments for patients worldwide. The company was founded in 2012 and is based in the Cleveland area, Ohio.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

ArmaGen, Inc. is a clinical-stage biotechnology company based in San Diego, California, specializing in the development of therapies for severe neurological diseases. The company focuses on lysosomal storage disorders and neurodegenerative diseases, including Hunter syndrome, Hurler syndrome, Sanfilippo A syndrome, and metachromatic leukodystrophy. ArmaGen's innovative product candidates, such as AGT-182 and AGT-181, are designed to penetrate the blood-brain barrier, allowing for more effective treatment of neurological complications associated with these conditions. Founded in 2001, ArmaGen aims to improve the quality of life for patients suffering from these challenging disorders through its targeted therapeutic approaches.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

LigoCyte Pharmaceuticals is a biotechnology company focused on developing innovative vaccines and therapeutic monoclonal antibodies aimed at treating inflammatory and infectious diseases. The company specializes in creating commercial vaccines and biodefense vaccines, with notable products including Norovirus VLP Vaccines, which mimic the live virus's surface configuration without causing infection, and an Influenza VLP Vaccine that offers protection against multiple strains, including A/H1N1 and A/H3N2. Additionally, LigoCyte is involved in the development of an anthrax vaccine and Anti-CD103 monoclonal antibodies, which play a role in the retention of activated lymphocytes at sites of inflammation. By advancing its proprietary products into human clinical testing, LigoCyte is positioned for growth in the biotechnology sector, contributing to the field of immunomodulatory drugs that target disease processes rather than merely alleviating symptoms.

Redwood Bioscience is a biotechnology company focused on precision protein-chemical engineering to develop optimized biotherapeutics. Established in 2008 and based in Emeryville, California, the company specializes in site-specific modification technology, which addresses the challenges of conjugating biologics with synthetic molecules. This innovative approach enables the creation of homogeneous hybrid biotherapeutics, enhancing the effectiveness of treatments. Redwood Bioscience's methods for optimizing drug conjugates leverage the binding specificity and extended half-life of biologic carriers while incorporating the potency advantages of small molecules and synthetic peptides, positioning the company at the forefront of advancements in antibody-drug conjugates and semi-synthetic biotherapeutics.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

Takeda Bio Development Center Limited engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. Takeda Bio Development Center Ltd. was formerly known as Amgen Kabushiki Kaisha. As a result of the acquisition of Amgen Kabushiki Kaisha by Takeda Pharmaceutical Co., Amgen Kabushiki Kaisha's name was changed. As of April 1, 2008, Takeda Bio Development Center Ltd. operates as a subsidiary of Takeda Pharmaceutical Co. Ltd.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

Xenon Pharmaceuticals is a biopharmaceutical company dedicated to developing novel medicines for neurological disorders. It focuses on rare genetic defects as drug targets, leveraging its proprietary discovery platform called Extreme Genetics. The company's pipeline includes XEN1101 and XEN496 for epilepsy treatment.

Receptor BioLogix is a biotechnology company based in Palo Alto, California, focused on developing receptor-based biological therapeutics aimed at treating cancer, inflammatory, and autoimmune diseases. The company specializes in creating Hermodulins, which are pan-HER ligand traps designed to inhibit the compensatory feedback mechanisms that can reduce the effectiveness and longevity of various cancer treatments. Additionally, Receptor BioLogix utilizes its Intron Fusion Protein platform to discover novel splice variants of human proteins, which hold therapeutic potential. Through these innovative approaches, the company aims to enhance treatment options and improve outcomes for patients with challenging medical conditions.